Plasma Homocysteine in Patients with Coronary and Carotid Artery Disease: A Case Control Study

Marijan Bosevski1,2, Nenad Zlatanovikj3, Danica Petkoska1

  • 1University Cardiology Clinic Skopje, Vascular Lab.

Insights

Elevated homocysteine (Hcy) levels are linked to increased cardiovascular disease (CAD) risk and atherosclerosis. This study found higher Hcy concentrations in patients with CAD and carotid artery disease, suggesting Hcy’s role in vascular disease development.

Area of Science:

  • Cardiovascular Medicine
  • Biochemistry
  • Pathology

Background:

  • Elevated plasma homocysteine (Hcy) is associated with endothelial damage, inflammation, and atherosclerosis progression.
  • Understanding the correlation between Hcy levels and cardiovascular disease (CAD) is crucial for risk stratification and management.

Purpose of the Study:

  • To evaluate the association between serum homocysteine levels and cardiovascular disease (CAD).
  • To investigate the role of Hcy in the development of atherosclerosis and vascular disease.

Main Methods:

  • A case-control analysis of 212 patients was conducted, categorizing them into low-risk, high-risk, symptomatic CAD, and CAD with carotid artery disease groups.
  • Plasma homocysteine levels were measured and correlated with various cardiovascular risk factors, disease severity, and intima-media thickness (IMT).

Main Results:

  • Significantly higher plasma homocysteine levels were observed in high-risk CAD patients and those with manifested CAD compared to controls.
  • Elevated Hcy was prevalent in patients with CAD (82.9%) and correlated with increased IMT and carotid artery disease.
  • Homocysteine levels showed correlations with CAD risk, WBC count, and specific risk factors in subgroups.

Conclusions:

  • High plasma homocysteine concentrations are significantly associated with an increased risk of vascular disease, including CAD and carotid artery disease.
  • These findings support a likely role for homocysteine in the inflammatory and metabolic pathways of atherosclerosis development.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
425
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
520
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
771
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
270
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
258
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
169